XRF Scientific Limited (XRF) AI Stock Analysis

• Market Cap: AU$328.88M
• Dividend Yield: 1.91%
• Average Volume (3M): 285.49K
• Price to Earnings (P/E): 31.7
• Beta (1Y): 0.96
• Revenue Growth: -1.09%
• EPS Growth: 14.88%
• Country: AU
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.04
• Shares Outstanding: 142,992,370
• 10 Day Avg. Volume: 266,938
• 30 Day Avg. Volume: 285,494
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.26
• Price Target Upside: -1.74% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: AU$2.50 ▲(8.70% Upside)

XRF Scientific Limited's strong financial performance and positive technical indicators are the primary drivers of its stock score. The company's profitability and solid balance sheet are strengths, but challenges in revenue growth and cash flow management need attention. The stock's valuation appears high, which could limit upside potential. Technical analysis suggests a strong upward trend, but caution is advised due to overbought signals.

XRF Scientific Limited Business Overview & Revenue Model

Company Description

XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries in Australia, Canada, and Europe. It operates through Capital Equipment, Precious Metals, and Consumables segments. The Capital Equipment segment designs, manufactures, and services automated fusion equipment, and high temperature test and production furnaces, as well as general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. The company was founded in 1972 and is based in Osborne Park, Australia.

How the Company Makes Money

XRF Scientific Limited generates revenue primarily through the sale of its proprietary equipment and consumables, which are used extensively in laboratory environments for sample preparation and analysis. The company offers a range of products including fusion machines, which are essential in preparing samples for X-ray fluorescence (XRF) analysis, a method widely used in the mining industry for determining the composition of materials. Additionally, XRF manufactures and sells platinum labware and certified reference materials that are critical for maintaining precision and standardization in analytical processes. The company's revenue streams are supported by its strong customer base in industries such as mining, construction materials, and research institutions. XRF also engages in partnerships and collaborations to enhance its market reach and technological capabilities, which further contribute to its financial performance.

XRF Scientific Limited Financial Statement Overview

Summary

XRF Scientific Limited demonstrates strong financial performance with robust profitability margins and low leverage, indicative of operational efficiency and financial stability. However, the company needs to focus on sustaining revenue growth and improving cash flow dynamics to ensure long-term financial health.

Income Statement

XRF Scientific Limited has shown a strong revenue growth rate of 8.45% from 2023 to 2024, with significant gross profit and net profit margins at 43.88% and 14.85% respectively for 2024. The company also maintains a robust EBIT margin of 24.15% and an EBITDA margin of 25.61%, indicating solid operational efficiency. However, monitoring future revenue growth is crucial to maintain this trajectory.

Balance Sheet

The company exhibits financial stability with a low debt-to-equity ratio of 0.06, reflecting conservative leverage. A healthy return on equity (ROE) of 16.19% suggests effective use of shareholders' funds. An equity ratio of 80.43% underscores strong financial independence, minimizing risk of solvency issues. Nonetheless, maintaining such low leverage might limit growth potential.

Cash Flow

XRF Scientific Limited experienced a decrease in operating cash flow to net income ratio from 2023 to 2024, but maintains a positive free cash flow to net income ratio of 0.73, indicating sufficient cash generation. However, the free cash flow growth rate declined by 15.56%, warranting attention to reverse this trend for sustained liquidity and investment capacity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	60.08M	59.45M	59.84M	55.17M	40.01M	31.29M
Gross Profit	27.43M	28.79M	26.27M	22.00M	16.46M	12.89M
EBITDA	15.97M	15.63M	15.32M	13.22M	9.44M	8.05M
Net Income	9.42M	10.38M	8.89M	7.69M	6.08M	5.13M
Balance Sheet
Total Assets	66.27M	72.79M	68.23M	65.55M	55.56M	48.37M
Cash, Cash Equivalents and Short-Term Investments	8.13M	12.23M	12.05M	10.40M	6.65M	5.26M
Total Debt	4.57M	4.41M	3.38M	4.31M	3.51M	1.44M
Total Liabilities	12.07M	12.62M	12.69M	15.97M	12.21M	9.27M
Stockholders Equity	54.21M	60.17M	54.89M	49.25M	43.48M	39.10M
Cash Flow
Free Cash Flow	9.37M	8.39M	6.45M	7.63M	2.63M	3.86M
Operating Cash Flow	10.37M	10.14M	8.09M	8.42M	3.15M	4.51M
Investing Cash Flow	-2.03M	-2.21M	-1.64M	-782.43K	-1.11M	-652.62K
Financing Cash Flow	-8.53M	-7.75M	-4.80M	-3.88M	-648.95K	-2.24M

XRF Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.17, above the 50-day MA of 2.10, and above the 200-day MA of 1.83, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 63.55 is Neutral, neither overbought nor oversold. The STOCH value of 71.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XRF	75 Outperform	AU$328.88M	31.71	18.05%	1.91%	-1.09%	14.88%
KAU	46 Neutral	AU$157.29M	-6.00	―	―	-41.05%	-122.11%
DTR	36 Underperform	AU$1.69B	-106.38	―	―	―	70.81%
GG8	36 Underperform	AU$277.88M	-79.63	―	―	―	72.45%
MTM	32 Underperform	AU$698.53M	-15.32	―	―	―	-186.15%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

XRF Scientific Limited Corporate Events

XRF Scientific Director Increases Shareholding

XRF Scientific Limited announced a change in the director’s interest, with Vance Stazzonelli acquiring 10,000 ordinary shares, increasing his total to 850,000 shares. This change, executed through a combination of off-market and on-market trades, reflects ongoing adjustments in the company’s leadership investments, potentially impacting stakeholder perceptions and the company’s market dynamics.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.